A5100336228- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Immune cells in cancer
- Psoriasis: Treatment and Pathogenesis
- Ferroptosis and cancer prognosis
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Peptidase Inhibition and Analysis
- Systemic Lupus Erythematosus Research
- Immunodeficiency and Autoimmune Disorders
- Monoclonal and Polyclonal Antibodies Research
- Single-cell and spatial transcriptomics
- Immune Response and Inflammation
- MicroRNA in disease regulation
- interferon and immune responses
- Asthma and respiratory diseases
- Cancer Genomics and Diagnostics
- Dermatology and Skin Diseases
- Cytomegalovirus and herpesvirus research
- Autoimmune and Inflammatory Disorders Research
- Epigenetics and DNA Methylation
- Inflammation biomarkers and pathways
- Aquaculture disease management and microbiota
Illinois College
2023
University of Illinois Urbana-Champaign
2023
University of Illinois Chicago
2023
Cleveland Clinic
2019-2022
First Hospital of Jilin University
2014-2022
Jilin University
2014-2022
Xuzhou Central Hospital
2022
The University of Texas at Arlington
2022
Blood Center of Zhejiang Province
2020
Medical College of Wisconsin
2014-2020
The immunoglobulin (Ig) superfamily consists of many critical immune regulators, including the B7 family ligands and receptors. In this study, we identify a novel structurally distinct Ig inhibitory ligand, whose extracellular domain bears homology to ligand PD-L1. This molecule is designated V-domain suppressor T cell activation (VISTA). VISTA primarily expressed on hematopoietic cells, expression highly regulated myeloid antigen-presenting cells (APCs) cells. A soluble VISTA-Ig fusion...
Abstract V-domain Ig suppressor of T-cell activation (VISTA) is a novel negative checkpoint ligand that homologous to PD-L1 and suppresses activation. This study demonstrates the multiple mechanisms whereby VISTA relieves regulation by hematopoietic cells enhances protective antitumor immunity. highly expressed on myeloid Foxp3+CD4+ regulatory cells, but not tumor within microenvironment (TME). monoclonal antibody (mAb) treatment increased number tumor-specific T in periphery enhanced...
Abstract V-domain Ig suppressor of T cell activation (VISTA) is a potent negative regulator T-cell function that expressed on hematopoietic cells. VISTA levels are heightened within the tumor microenvironment, in which its blockade can enhance antitumor immune responses mice. In humans, related programmed death 1 (PD-1) pathway has shown great potential clinical immunotherapy trials. Here, we report structure human and examine lymphocyte regulation cancer. predominantly compartment with...
V-domain immunoglobulin suppressor of T-cell activation (VISTA) is a negative immune-checkpoint protein that suppresses responses. To determine whether VISTA synergizes with another immune-checkpoint, programmed death 1 (PD-1), this study characterizes the immune responses in VISTA-deficient, PD-1-deficient (KO) mice and VISTA/PD-1 double KO mice. Chronic inflammation spontaneous T cells were observed both single mice, demonstrating their nonredundancy. However, exhibited significantly...
Abstract In the past few years, field of cancer immunotherapy has made great progress and is finally starting to change way treated. We are now learning that multiple negative checkpoint regulators (NCR) restrict ability T-cell responses effectively attack tumors. Releasing these brakes through antibody blockade, first with anti-CTLA4 followed by anti-PD1 anti-PDL1, emerged as an exciting strategy for treatment. More recently, a new NCR surfaced called V-domain immunoglobulin (Ig)-containing...
V domain-containing Ig suppressor of T-cell activation (VISTA) is a negative checkpoint regulator that suppresses T cell-mediated immune responses. Previous studies using VISTA-neutralizing monoclonal antibody show VISTA blockade enhances activation. The current study describes comprehensive characterization mice in which the gene for has been deleted. Despite apparent normal hematopoietic development young mice, genetic deficiency leads to gradual accumulation spontaneously activated cells,...
Abstract Immune-checkpoint protein V-domain immunoglobulin suppressor of T-cell activation (VISTA) controls antitumor immunity and is a valuable target for cancer immunotherapy. This study identified role VISTA in regulating Toll-like receptor (TLR) signaling myeloid cells controlling cell–mediated inflammation immunosuppression. modulated the polyubiquitination expression TRAF6. Consequently, dampened TLR-mediated MAPK/AP-1 IKK/NF-κB cascades. At cellular levels, regulated effector...
V-domain Immunoglobulin Suppressor of T cell Activation (VISTA) is an inhibitory immune-checkpoint molecule that suppresses CD4+ and CD8+ activation when expressed on antigen-presenting cells. Vsir -/- mice developed loss peripheral tolerance multi-organ chronic inflammatory phenotypes. cells were hyper-responsive towards self- foreign antigens. Whether or not VISTA regulates innate immunity unknown. Using a murine model psoriasis induced by TLR7 agonist imiquimod (IMQ), we show deficiency...
Objective. To elucidate the potential role of follicular helper T cells (TFH) and interleukin 10 (IL-10)+ B in development systemic lupus erythematosus (SLE). Methods. The numbers peripheral blood CD27+, CD38+, CD86+, CD95+, IL-10+ cells, inducible cell costimulator (ICOS)+, programmed death-1 (PD-1)+, IL-21+, CXCR5+CD4+ TFH-like were examined 23 patients with new onset SLE 20 healthy controls (HC). Results In comparison HC, significantly reduced CD19+ but increased CD27 high , CD95+...
Programmed cell death 1 (PD-1) is a key regulatory molecule that has been targeted in human cancers, including melanoma. In clinical testing, Abs against PD-1 have resulted psoriasiform dermatitis (PsD). To determine whether regulates PsD, we compared skin responses of PD-1-deficient (PD-1KO) mice and wild-type (WT) controls an imiquimod (IMQ)-induced murine model psoriasis. PD-1KO showed severe epidermal hyperplasia, greater neutrophilic infiltration, higher expression Th17 cytokines...
Immunotherapies targeting CTLA-4 and PD-1 have elicited promising responses in a variety of cancers. However, the relatively low response rates warrant identification additional immunosuppressive pathways. V domain immunoglobulin suppressor T cell activation (VISTA) plays critical role antitumor immunity is valuable target cancer immunotherapy.Here, we used single-cell RNA-seq to analyze gene expression levels 14897 cells from breast sample its paired 7,320 normal cells. Then, validated...
In addition to activated T cells, the immune checkpoint inhibitor "V domain-containing Ig suppressor of T-cell activation" (VISTA) is expressed by myeloid cell types, including macrophages and neutrophils. The importance VISTA expression cells antibody-induced arthritis its potential for relevance in human disease was evaluated. immunolocalized normal arthritic synovial tissue sections lysates were subjected western blot analysis. collagen model (CAIA) performed with DBA/1 J mice treated...
Abstract B‐cell‐activating factor (BAFF), a member of the tumour necrosis superfamily, plays critical role in maturation, homeostasis and function B cells. In this study, we demonstrated biological outcome BAFF blockade BXSB murine lupus model, using soluble fusion protein consisting human BAFF‐R mutant IgG4 Fc. Mutation Leu 235 to Glu Fc eliminated antibody‐dependent cell cytotoxicity (ADCC) complement lysis activity, generated devoid immune effector functions. Treatment mice with...
Autoreactive B cells are the source of pathogenic autoantibodies (autoAb) in systemic lupus erythematosus (SLE). Previous studies have demonstrated that anti-small nuclear ribonucleoprotein particles (snRNP) from normal background mice tolerize T periphery and do not secrete autoAb. In this study, we examined whether these anti-snRNP can be activated for autoAb production by engagement Toll-like receptors (TLR). Anti-snRNP proliferated vigorously secreted abundant upon exposure to CpG or...
Abstract Aim The dysfunction of T regulatory cells is important for the pathogenesis systemic lupus erythematosus ( SLE ). Glucocorticoid‐induced tumor necrosis factor receptor family‐related protein GITR ) expressed at low levels on resting responder lymphocytes (Tresps) and up‐regulated (Tregs) activated cells, diminishing suppressive activity Tregs and/or leading to resistance suppression by effector cells. We aimed explore whether patients had an aberrant expression regulation...
The objective of this study is to detect the number different subsets TFH and B cells in renal transplant recipients (RTR) with antibody-mediated acute rejection (AMR), (AR), chronic (CR), or stable (TS). present was a prospective study. numbers ICOS +, PD-1+ IL-21+ TFH, CD86+, CD38+, CD27+, IgD- 21 patients end-stage disease (ESRD) post-transplant times were measured by flow cytometry. level serum IL-21 detected ELISA. circulating CD4+CXCR5+, CD4+CXCR5+ICOS+, CD4+CXCR5+PD-1+,...
HLA‐A*31:01:34 differs from HLA‐A*31:01:02:01 by one nucleotide substitution at position 123 C>G.